

Notice of Allowability	Application No.	Applicant(s)
	10/715,632	MENDELSON ET AL.
	Examiner Kagnew H. Gebreyesus	Art Unit 1652

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTO-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. This communication is responsive to June 7, 2005.
2. The allowed claim(s) is/are 5, 6, 7 and 8.
3. The drawings filed on 17 November 2003 are accepted by the Examiner.
4. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) All
 - b) Some*
 - c) None
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.
THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

5. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
6. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
 - (a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
 - 1) hereto or 2) to Paper No./Mail Date _____.
 - (b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.
7. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. Notice of References Cited (PTO-892)
2. Notice of Draftsperson's Patent Drawing Review (PTO-948)
3. Information Disclosure Statements (PTO-1449 or PTO/SB/08),
Paper No./Mail Date 5/05
4. Examiner's Comment Regarding Requirement for Deposit
of Biological Material
5. Notice of Informal Patent Application (PTO-152)
6. Interview Summary (PTO-413),
Paper No./Mail Date _____.
7. Examiner's Amendment/Comment
8. Examiner's Statement of Reasons for Allowance
9. Other _____.

DETAILED ACTION

1. Applicant's response with amendments to claims filed on May 05, 2005 has been acknowledged. Claims 1-4, 9-35 have been cancelled. Claim 5-8 and new claim 36 are under consideration.
2. However the following amendment to claim 5 was suggested by the examiner as claim 5 as presented in the amendment filed on May 5, 2005 by applicant was beyond the scope of enablement provided by the specification. The following amendment was presented to applicant for consideration on June 07, 2005:

Claim 5. A substantially pure nucleic acid molecule of SEQ ID NO: 19 that encodes a polypeptide that binds myosin phosphatase, RhOA or both.

In response to the above suggested amendment, applicant agreed and authorized the following final amendments to the claims.

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Attorney Cooper McDonald on June 10, 2005.

Art Unit: 1652

Claim 5. A substantially pure nucleic acid molecule comprising SEQ ID NO: 19 wherein said nucleic acid encodes a polypeptide that binds myosin phosphatase, RhOA or both.

Claim 6. The nucleic acid molecule of claim 5, wherein said nucleic acid encodes a human M-RIP protein.

Claim 7. The nucleic acid molecule of claim 5, wherein said nucleic acid has the nucleic acid sequence of SEQ ID NO: 19.

8. The nucleic acid molecule of claim 5, wherein said nucleic acid encodes a polypeptide having an amino acid sequence of SEQ ID NO: 1

Claim 36 cancelled.

Reason for allowance:

3. The following is an examiner's statement of reasons for allowance:

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Although a sequence showing 99.5% sequence identity to SEQ ID NO: 19 was found in the prior art, given that one of the guidelines for patentability is novelty and that no motivation was found to deny any new attribute to the variation in SEQ ID NO: 19 from the prior art the claims as amended have been allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kagnew H Gebreyesus whose telephone number is 571-272-2937. The examiner can normally be reached on 8:30 am-5:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Achutamurthy ponnathapura can be reached on 571-272-0928. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Kagnew Gebreyesus PhD.



REBECCA E. PROUTY
PRIMARY EXAMINER
GROUP 1800
(600)